Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1994 Feb;37(2):199–204. doi: 10.1111/j.1365-2125.1994.tb04261.x

Does tachyphylaxis occur to the non-pulmonary effects of salmeterol?

J G Maconochie 1, N A Minton 1, J E Chilton 1, O N Keene 1
PMCID: PMC1364598  PMID: 7910472

Abstract

1. The potential for tachyphylaxis to the non-pulmonary effects of salmeterol, a long-acting selective beta 2-adrenoceptor agonist was investigated in 12 healthy male subjects in a double-blind two period crossover study design. 2. Subjects received cumulative doses of up to 400 micrograms (50 + 50 + 100 + 100 + 100 micrograms at 45 min intervals) inhaled salmeterol prior to a 13 day dosing schedule of twice-daily inhaled salmeterol 100 micrograms or placebo. Twelve hours after the last dose of salmeterol or placebo, subjects again received cumulative doses of up to 400 micrograms inhaled salmeterol. 3. Pulse rate, blood pressure, 12-lead ECG, physiological tremor and peak expiratory flow rate (PEFR) were measured before administration of cumulative doses of salmeterol, at 10, 20, 30 and 40 min after each incremental dose of salmeterol and at 4, 6 and 8 h after the first dose. Blood samples were taken for plasma potassium, magnesium, non-esterified fatty acids (NEFA) and blood glucose concentrations at 20 and 40 min after each dose and at 4, 6 and 8 h after the first dose. 4. Eleven subjects completed the study. One subject withdrew due to beta 2-adrenoceptor related adverse events. All other adverse events reported were mild in nature. 5. Dose-related changes to the effects of salmeterol on pulse rate, QTc interval, tremor, PEFR, blood glucose and plasma potassium were seen, but there was no dose-related effect of salmeterol on blood pressure, plasma magnesium and NEFA. 6. Tachyphylaxis occurred to the effects of salmeterol on tremor, QTc and blood glucose.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
199

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Crane J., Burgess C., Beasley R. Cardiovascular and hypokalaemic effects of inhaled salbutamol, fenoterol, and isoprenaline. Thorax. 1989 Feb;44(2):136–140. doi: 10.1136/thx.44.2.136. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Harvey J. E., Baldwin C. J., Wood P. J., Alberti K. G., Tattersfield A. E. Airway and metabolic responsiveness to intravenous salbutamol in asthma: effect of regular inhaled salbutamol. Clin Sci (Lond) 1981 May;60(5):579–585. doi: 10.1042/cs0600579. [DOI] [PubMed] [Google Scholar]
  3. Holgate S. T., Baldwin C. J., Tattersfield A. E. beta-adrenergic agonist resistance in normal human airways. Lancet. 1977 Aug 20;2(8034):375–377. doi: 10.1016/s0140-6736(77)90304-x. [DOI] [PubMed] [Google Scholar]
  4. Holgate S. T., Stubbs W. A., Wood P. J., McCaughey E. S., Alberti K. G., Tattersfield A. E. Airway and metabolic resistance to intravenous salbutamol: a study in normal man. Clin Sci (Lond) 1980 Sep;59(3):155–161. doi: 10.1042/cs0590155. [DOI] [PubMed] [Google Scholar]
  5. Jenne J. W. Whither beta-adrenergic tachyphylaxis? J Allergy Clin Immunol. 1982 Dec;70(6):413–416. doi: 10.1016/0091-6749(82)90002-1. [DOI] [PubMed] [Google Scholar]
  6. Kenward M. G., Jones B. The analysis of data from 2 x 2 cross-over trials with baseline measurements. Stat Med. 1987 Dec;6(8):911–926. doi: 10.1002/sim.4780060806. [DOI] [PubMed] [Google Scholar]
  7. Koch G. G. The use of non-parametric methods in the statistical analysis of the two-period change-over design. Biometrics. 1972 Jun;28(2):577–584. [PubMed] [Google Scholar]
  8. Lipworth B. J., Clark R. A., Fraser C. G., McDevitt D. G. The biochemical effects of high-dose inhaled salbutamol in patients with asthma. Eur J Clin Pharmacol. 1989;36(4):357–360. doi: 10.1007/BF00558295. [DOI] [PubMed] [Google Scholar]
  9. Lipworth B. J., Tregaskis B. F., McDevitt D. G. Comparison of hypokalaemic, electrocardiographic and haemodynamic responses to inhaled isoprenaline and salbutamol in young and elderly subjects. Eur J Clin Pharmacol. 1991;40(3):255–260. doi: 10.1007/BF00315205. [DOI] [PubMed] [Google Scholar]
  10. Maconochie J. G., Forster J. K. Dose-response study with high-dose inhaled salmeterol in healthy subjects. Br J Clin Pharmacol. 1992 Mar;33(3):342–345. doi: 10.1111/j.1365-2125.1992.tb04049.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Schaffler K., Reeh P. W. Induction and reduction of muscle tremor upon acute and repeated administration of the beta 2-agonists terbutaline, salbutamol and tulobuterol. Int J Clin Pharmacol Ther Toxicol. 1987 Dec;25(12):673–682. [PubMed] [Google Scholar]
  12. Smith S. R., Kendall M. J. Downgrading of biochemical and cardiovascular responses to an intravenous infusion of terbutaline following chronic treatment with oral terbutaline. Int J Clin Pharmacol Ther Toxicol. 1986 Jan;24(1):1–3. [PubMed] [Google Scholar]
  13. Surawicz B. Relationship between electrocardiogram and electrolytes. Am Heart J. 1967 Jun;73(6):814–834. doi: 10.1016/0002-8703(67)90233-5. [DOI] [PubMed] [Google Scholar]
  14. Ullman A., Hedner J., Svedmyr N. Inhaled salmeterol and salbutamol in asthmatic patients. An evaluation of asthma symptoms and the possible development of tachyphylaxis. Am Rev Respir Dis. 1990 Sep;142(3):571–575. doi: 10.1164/ajrccm/142.3.571. [DOI] [PubMed] [Google Scholar]
  15. Ullman A., Svedmyr N. Salmeterol, a new long acting inhaled beta 2 adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients. Thorax. 1988 Sep;43(9):674–678. doi: 10.1136/thx.43.9.674. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Wager J., Fredholm B. B., Lunell N. O., Persson B. Development of tolerance to oral salbutamol in the third trimester of pregnancy: a study of circulatory and metabolic effects. Br J Clin Pharmacol. 1981 Oct;12(4):489–495. doi: 10.1111/j.1365-2125.1981.tb01255.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Williams S. J., Winner S. J., Clark T. J. Comparison of inhaled and intravenous terbutaline in acute severe asthma. Thorax. 1981 Aug;36(8):629–631. doi: 10.1136/thx.36.8.629. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Wong C. S., Pavord I. D., Williams J., Britton J. R., Tattersfield A. E. Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma. Lancet. 1990 Dec 8;336(8728):1396–1399. doi: 10.1016/0140-6736(90)93099-b. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES